Gastroesophageal Reflux Clinical Trial
Official title:
Effects of Diet and Alcohol on Fullness, Reflux and Dyspeptic Symptoms After Meals
Verified date | June 2015 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Observational |
Reflux and dyspeptic symptoms are common affecting 10-20% of the population on a regular
basis. Reflux symptoms such as heartburn and regurgitation are caused by the return of acid
or non-acid gastric contents into the esophagus. Dyspeptic symptoms are caused by abnormal
gastric relaxation (impaired accommodation) or increased sensitivity of the stomach to
distension during the meal.
The effects of diet on gastrointestinal function are debated and the efficacy of dietary
management for digestive symptoms has not been established. Epidemiological studies suggest
an effect; however, it is not possible to distinguish the effects of fat intake and total
energy (i.e. calorie) intake in this work. This issue has been addressed by small
physiological studies. The results show that esophageal acid exposure was related to total
calorie intake but not to fat content. In contrast, the number of reflux symptoms was 40%
higher after the high-fat than the low-fat meals. Similar findings were found for the
relationship between gastric distension, fullness and dyspeptic symptoms by Magnetic
Resonance Imaging. Thus, it appears that fat does not cause digestive dysmotility but
heightens sensitivity to visceral events and so increases the number and severity of
symptoms reported by patients. As yet, these findings have not been confirmed in larger,
more representative surveys.
Similar to the effects of food, there are inconsistent findings regarding the effects of
alcohol on gastro-esophageal reflux (GER) and gastric function. Physiological studies have
noted delayed gastric emptying and an increase in reflux events when alcohol is taken with
food. However, larger surveys have not confirmed that alcohol triggers reflux or dyspeptic
symptoms.
The proposed observational, dietary study with cross-over design will assess the independent
effects of energy intake (i.e. calorie load) and fat intake on gastric fullness, the number
and severity of reflux and dyspeptic symptoms after meals. The effect of alcohol on symptoms
after the high calorie, high fat meals will also be documented. The study population of
senior academics attending a conference are likely to have a relatively high prevalence of
risk factors for gastro-esophageal reflux disease (GERD) being predominantly male, with an
older age and a larger waist circumference than average in the general community. This will
increase study power and relevance of the findings.
The results will provide new information concerning the impact of dietary factors and
alcohol on digestive symptoms after meals. This data will inform future guidelines for the
dietary management of patients with reflux and dyspeptic symptoms after meals which will be
relevant in both primary and secondary care.
Status | Completed |
Enrollment | 84 |
Est. completion date | April 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participants will be faculty and delegates attending the "Ascona II: Advances in clinical measurement of gastrointestinal motility and function" conference. Exclusion Criteria: - Age < 18, - special dietary requirements incompatible with meals served at congress hotel restaurant, - participation in another study with investigational drug within the 30 days preceding and during the present study (purely diagnostic studies are acceptable), - individuals unwilling to provide written informed consent, - inability to follow the procedures of the study, e.g. due to language problems (all study documents in English). Participants with a history of alcohol dependency or medical conditions that may be exacerbated or affected by alcohol intake are allowed to participate but are instructed not to drink the alcohol provided with the high calorie, high fat test meal on day 4. |
Observational Model: Case-Crossover, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005 May;54(5):710-7. Review. — View Citation
DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005 Jan;100(1):190-200. — View Citation
Fox M, Barr C, Nolan S, Lomer M, Anggiansah A, Wong T. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007 Apr;5(4):439-44. Epub 2007 Mar 23. — View Citation
Fox M, Forgacs I. Gastro-oesophageal reflux disease. BMJ. 2006 Jan 14;332(7533):88-93. Review. — View Citation
Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, Hungin AP, Batchelor HK. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008 Feb 1;27(3):249-56. Epub 2007 Oct 31. — View Citation
Zheng Z, Nordenstedt H, Pedersen NL, Lagergren J, Ye W. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology. 2007 Jan;132(1):87-95. Epub 2006 Nov 17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Quality of Life measured by EQ-5D Quality of Life questionnaire | A 5-item index score, the VAS score and the utility score (composite score calculated from the first two scores) from the EQ-5D Quality of Life questionnaire. | Participants will be followed for the duration of the conference, an expected average of 4 days | No |
Other | Postprandial Distress measured by Leuven dyspepsia questionnaire | A composite score from Leuven dyspepsia questionnaire will be analysed | Participants will be followed for the duration of the conference, an expected average of 4 days | No |
Other | Safety outcome measured by the number of severe reflux symptoms | Severe reflux symptom was defined as >60% on the visual-to-analogue scale form 0 to 100 | Participants will be followed for the duration of the conference, an expected average of 4 days | Yes |
Other | Safety outcome measured by the number of severe dyspeptic symptoms | Severe dyspeptic symptom was defined as >60% on the visual-to-analogue scale form 0 to 100 | Participants will be followed for the duration of the conference, an expected average of 4 days | Yes |
Primary | Number of reflux symptoms | Similar to "Pharmacokinetic outcome measures" the occurrence of reflux symptoms after each dinner will be summed up and compared between different dinners. | Participants will be followed for the duration of the conference, an expected average of 4 days | No |
Primary | Number of dyspeptic symptoms | Similar to "Pharmacokinetic outcome measures" the occurrence of dyspeptic symptoms after each dinner will be summed up and compared between different dinners. | Participants will be followed for the duration of the conference, an expected average of 4 days | No |
Secondary | The severity of reflux symptoms measured by a visual-to-analogue scale from 0 to 100 | Participants will be followed at time points -30 min (before dinner) and at 0, 30, 60, 90, 120, 150, 180 min (after dinner) for 4 consecutive days | No | |
Secondary | The severity of dyspeptic symptoms measured by a visual-to-analogue scale from 0 to 100 | Participants will be followed at time points -30 min (before dinner) and at 0, 30, 60, 90, 120, 150, 180 min (after dinner) for 4 consecutive days | No | |
Secondary | The sensation of fullness measured by a visual-to-analogue scale from 0 to 100 | Participants will be followed at time points -30 min (before dinner) and at 0, 30, 60, 90, 120, 150, 180 min (after dinner) for 4 consecutive days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |